Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Expert Review of Anti-infective Therapy Année : 2021

Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH)

David Zucman
Laure Esterle
Linda Wittkop

Résumé

Background: Cannabis use and elevated fatty liver index (FLI≥ 60) (a biomarker of hepatic steatosis in the general population) have been identified as predictors of HCV-related and overall mortality, respectively, in HIV-HCV co-infected patients. However, the relationship between cannabis use and the risk of elevated FLI has never been explored. Methods: Using five-year follow-up data from 997 HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort), we analyzed the relationship between cannabis use and FLI using mixed-effects multivariable logistic (outcome: elevated FLI yes/no) and linear (outcome: continuous FLI) regression models. Results: At the last follow-up visit, 27.4% of patients reported regular or daily cannabis use and 27.8% had elevated FLI. After multivariable adjustment, regular or daily cannabis use was associated with a 55% lower risk of elevated FLI (adjusted odds ratio [95% confidence interval]: 0.45 [0.22; 0.94]; p = 0.033) and lower FLI values (adjusted model coefficient: -4.24 [-6.57; -1.91], p<0.0001). Conclusions: Cannabis use is associated with a reduced risk of elevated fatty liver index in HIV-HCV co-infected patients. Further research is needed to confirm whether and how cannabinoids may inhibit the development of hepatic steatosis or other metabolic disorders in high-risk populations.
Fichier non déposé

Dates et versions

hal-03185691 , version 1 (30-03-2021)

Identifiants

Citer

Tangui Barre, Teresa Rojas Rojas, Karine Lacombe, Camelia Protopopescu, Isabelle Poizot-Martin, et al.. Cannabis use and reduced risk of elevated fatty liver index in HIV-HCV co-infected patients: a longitudinal analysis (ANRS CO13 HEPAVIH). Expert Review of Anti-infective Therapy, 2021, 19 (9), pp.1147-1156. ⟨10.1080/14787210.2021.1884545⟩. ⟨hal-03185691⟩
58 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More